We found that six out of seven LBD+AD cases are above this cut‐off (i.e., greater intermediate‐to‐high tau pathology) while in the less affected primary visual cortex ROI, the same threshold was surpassed only in two LBD+AD participants [STC vs. VIS: x2 = 4.7, P < 0.05]. This evidence concerns the gene MAPT and Alzheimer disease.